Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Press Release

<< Previous

Bullboard Posts

Next >>

Comment by mercedesmanon Jun 20, 2023 9:40am

173 Views

Post# 35504948

RE:Press Release

Yah, you're nitpicking.

It's the sixty-fourth anniversary of your first purchase of EDT - worthy of mention.

When they get to 128, thta'll be emblematic of your average cost base ($ 1.28) - also a milestone worthy of celebration.

Personally I am in favour of regular updates, as it highlites the nonsensicality of the statements that the FUD community (i.e. set of aliases) continue to spew (e.g they are no longer saying "exceeding expectations", or "at this rate we'll reach 90 in 7 years", etc.)

The enrollment rate experienced over the past ten weeks maintains the target timeline of 90 patients enrolled around the end of 2023.
On track to have 25 active trial sites open by the end of September 2023, with 3 new sites anticipated to be open for enrollment in June 2023.
New CRO transition progressing on schedule, with full transition expected to be complete by the end of June.
Crude 28-day mortality results, thus far, continue to exceed efficacy targets.